{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:24:15Z","timestamp":1761823455655,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":471,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.vaccine.2012.02.039","type":"journal-article","created":{"date-parts":[[2012,2,29]],"date-time":"2012-02-29T08:16:40Z","timestamp":1330503400000},"page":"2989-2998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age"],"prefix":"10.1016","volume":"30","author":[{"given":"Roger","family":"Baxter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth L.","family":"Toback","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frangiscos","family":"Sifakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Aukes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ned","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xionghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.02.039_bib0005","first-page":"1","article-title":"Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"53","author":"Harper","year":"2004","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2012.02.039_bib0010","first-page":"1","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010","volume":"59","author":"Fiore","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2012.02.039_bib0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/01.inf.0000109392.96411.4f","article-title":"Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents","volume":"23","author":"Bergen","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2012.02.039_bib0020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMoa065368","article-title":"Live attenuated versus inactivated influenza vaccine in infants and young children","volume":"356","author":"Belshe","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.02.039_bib0025","doi-asserted-by":"crossref","first-page":"D10","DOI":"10.1016\/j.vaccine.2008.06.083","article-title":"Safety and efficacy of live attenuated influenza vaccine in children 2\u20137 years of age","volume":"26","author":"Belshe","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.02.039_bib0030","unstructured":"US Food and Drug Administration (FDA) approves nasal influenza vaccine for use in younger children US Food and Drug Administration. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2007\/ucm108988.htm [accessed 06.05.11]."},{"key":"10.1016\/j.vaccine.2012.02.039_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/j.1750-2659.2011.00243.x","article-title":"An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2\u201317 years","author":"Ambrose","year":"2011","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2012.02.039_bib0040","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1542\/peds.2004-2258","article-title":"Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5\u20139 years, and 10\u201318 years of age in a community-based, nonrandomized, open-label trial","volume":"116","author":"Piedra","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2012.02.039_bib0045","first-page":"1100","article-title":"Cox's regression model counting process: a large sample study","volume":"10","author":"Anderson","year":"1982","journal-title":"Ann Stat"},{"key":"10.1016\/j.vaccine.2012.02.039_bib0050","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1016\/j.vaccine.2010.01.060","article-title":"A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children","volume":"28","author":"Zhu","year":"2010","journal-title":"Vaccine"},{"year":"2010","series-title":"National hospital discharge survey: 2007 summary","author":"Hall","key":"10.1016\/j.vaccine.2012.02.039_bib0055"},{"key":"10.1016\/j.vaccine.2012.02.039_bib0060","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.294.21.2720","article-title":"Adverse events reported following live, cold-adapted, intranasal influenza vaccine","volume":"294","author":"Izurieta","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2012.02.039_bib0065","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199805143382002","article-title":"The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children","volume":"338","author":"Belshe","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.02.039_bib0070","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0022-3476(00)70097-7","article-title":"Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A\/Sydney) not contained in the vaccine","volume":"136","author":"Belshe","year":"2000","journal-title":"J Pediatr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12002332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12002332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:13:46Z","timestamp":1759400026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12002332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":14,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0264410X12002332"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.02.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.02.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}